Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Ariel Focus Fund Ariel Investments, LLC | “Bio-Rad was repurchased by the fund because of its dominant market share in key life science categories and diversified global footprint. The company has growing operating margins and a high share of recurring revenues, positioning it well to capture growth in clinical diagnostics and biopharma.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Longleaf Partners Global Fund Ross Glotzbach | “Bio-Rad – Life-sciences companies Bio-Rad and Avantor combined to detract from our performance this year. We entered the year owning only Bio-Rad. The company got off to a rough start with a disappointing set of results compounded by large industry headwinds as a result of US government-driven research spending cutbacks. The good news on Bio-Rad was that it repurchased shares at a strong pace in the first half of the year and avoided large, value-destructive M&A. The company also showed operational improvement and should be in a better position to grow FCF in 2026 and beyond. BSD Analysis: Bio-Rad is a quietly dominant life sciences tools company with deep roots in diagnostics and research workflows. Demand cycles ebb with funding, but the installed base creates recurring consumables revenue that stabilizes cash flow. The company's technological depth makes it sticky in labs that don't like switching critical systems. Margin pressure has masked the durability of the model. Investors often compare Bio-Rad to faster-growing peers and miss its resilience. Long-term growth tracks scientific complexity, not funding headlines. This is a steady compounder hiding behind cyclical noise.” | BULL | Q4 2025 Jan 1, 2026 | View Pitch |
First Eagle Investments James Fellows | “Bio-Rad is a highly integrated leader in specialized niches of diagnostics and life sciences, benefiting from high barriers to entry and strong recurring revenue. The company possesses significant hidden asset value via a major equity stake in Sartorius and features highly aligned family leadership.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
First Eagle Investments James Fellows | “Healthcare has been out of favor in recent years, weighed down by post-Covid headwinds, but we find the highly regulated sector to be structurally attractive given growing demand and significant barriers to entry. With a market cap around $6.5 billion, Bio-Rad Laboratories is smaller than our typical investment, but the company dominates the niches it serves within the areas of life-science research and diagnostics. Vertical integration historically has resulted in strong recurring revenue for the company, and its diversified customer base has further supported stability. Notably, Bio-Rad maintains a one-third stake in German biopharma company Sartorius that has grown significantly since its purchase and provides Bio-Rad with an economic exposure beyond its core businesses. Founded in a Quonset hut in 1952 by a husband-wife pair of Cal Berkeley graduates and run by their son since 2003, Bio-Rad maintains a family orientation that aligns interests with shareholders and contributes to the long-term orientation we look for in management teams. BSD Analysis: Bio-Rad is a niche-dominant life sciences tools company with recurring revenue, high switching costs, and strong barriers to entry. The embedded value of its Sartorius stake adds hidden asset value not fully reflected in the share price. Healthcare's regulatory complexity favors incumbents with scale and expertise, supporting long-term cash flow durability. Family-led governance aligns capital allocation with long-term value creation. Upside catalysts include recovery in life science spending and monetization or revaluation of the Sartorius stake. Risks include prolonged funding pressure in research budgets.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Madison Mid Cap Fund Haruki Toyama, Andy Romanowich, Rich Eisinger | “Bio-Techne is a leader in the life sciences research market with a broad portfolio of products that are used to enable discoveries of new drugs, therapeutics, and diagnostics. Around 80% of the business is recurring revenues. We are encouraged by the new CEO's strategy to leverage the core business and expand the company's leadership position in protein research. Consternation surrounding the health of customer research spending gave us the opportunity to buy the stock at a discount to our estimate of intrinsic value. BSD Analysis: Bio-Techne sells mission-critical reagents and tools embedded deep in life sciences workflows. Biotech funding cycles create demand pauses, not customer churn. Validation and reproducibility requirements create high switching costs. Margins reflect specialization, not scale hype. Investors confuse destocking with decay. As research funding normalizes, volume snaps back quickly. The installed base quietly compounds consumables revenue. Operating leverage cuts both ways. This is picks-and-shovels science tested by patience.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Longleaf Partners Fund Southeastern Asset Management, Inc. | “Bio-Rad Laboratories, a healthcare products manufacturer, was a positive contributor after the company reported steadier earnings than the market expected in a difficult environment. This sets the company up for the ability to grow earnings in 2026 and beyond, more in-line with previous industry trends. The company's important investment in Sartorius has also shown encouraging year-over-year trends following a difficult couple of years, and we are getting closer to a period when both companies will have increased strategic flexibility. In the meantime, Bio-Rad continues to be a material share repurchaser with its nearly net cash balance sheet. BSD Analysis: Bio-Rad remains one of the most technically credible players in life-science tools, with IP depth in PCR, antibodies, and immunology that gives it a durable niche even in a sluggish funding environment. The company's operational reset is working — cost actions are lifting margins and the balance sheet is clean. End-market softness is real, but Bio-Rad's recurring consumables base keeps earnings more stable than bears admit. The market still prices BIO like a stalled instruments company, not a high-ROIC specialty tools provider with improving execution. As research spending normalizes, Bio-Rad looks positioned for a solid margin and sentiment rebound.” | BULL | Q3 2025 Oct 1, 2025 | View Pitch |
Ariel Small Cap Value Strategy Ariel Investments, LLC | “The manager initiated a new position in Bio-Rad, citing its diversified global customer base and strong financial profile. The company features highly recurring revenue streams and holds dominant market shares in its key product categories.” | BULL | Q1 2025 Mar 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
